MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$2,633K
Net Income
-$11,144K
Net Profit Margin
-423.24%
EPS
-$0.08
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Product sales, net
2,633
899
9,561
4,952
Cost of goods sold
511
410
2,592
905
Loss on change in accounting estimates on contingent royalty liability (note 7)
-
-
-3,866*
1,933
Amortization of intangible asset
14
75
96
80
Research and development, net
694
518
-3,501*
470
Selling and marketing
2,075
2,093
2,066
2,391
General and administrative
1,828
2,372
1,097
2,088
Total operating expenses
5,122
5,468
6,216
4,001
Loss from operations
-2,489
-4,569
3,345
951
Interest income
3
2
2
3
Other expense, net
613
737
691
682
Loss on debt extinguishment
-2,192
-
-
-
Change in fair value of financial instruments
-5,745
-162
131
-1,845
Total other income (expense), net
-8,547
-897
-558
-2,524
Loss before income tax expense
-11,036
-5,466
2,787
-1,573
Income tax expense
-
-1
-1
-4
Net loss
-11,036
-5,465
2,788
-1,569
Convertible and redeemable preferred stock deemed dividends
108
20
2
111
Net loss attributable to common stockholders
-11,144
-5,485
2,786
-1,680
Basic EPS
-0.08
-0.04
0.019
-0.01
Diluted EPS
-0.08
-0.04
0
-0.01
Basic Average Shares
137,337,773
133,246,864
146,011,189
119,578,093
Diluted Average Shares
137,337,773
133,246,864
6,421,746,555*
119,578,093
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$11,144K
(-524.31%↓ Y/Y)
Net loss
-$11,036K
(-518.61%↓ Y/Y)
Convertible and redeemable
preferred stock deemed...
$108K
(10900.00%↑ Y/Y)
Loss before income
tax expense
-$11,036K
(-521.05%↓ Y/Y)
Total other income
(expense), net
-$8,547K
(-1524.90%↓ Y/Y)
Loss from operations
-$2,489K
(-98.96%↓ Y/Y)
Interest income
$3K
(50.00%↑ Y/Y)
Product sales, net
$2,633K
(-45.43%↓ Y/Y)
Change in fair value of
financial instruments
-$5,745K
(-4387.31%↓ Y/Y)
Loss on debt
extinguishment
-$2,192K
Other expense, net
$613K
(-7.40%↓ Y/Y)
Total operating
expenses
$5,122K
(-15.70%↓ Y/Y)
Selling and marketing
$2,075K
(-20.95%↓ Y/Y)
General and
administrative
$1,828K
(-0.81%↓ Y/Y)
Research and
development, net
$694K
(-6.97%↓ Y/Y)
Cost of goods sold
$511K
(-32.32%↓ Y/Y)
Amortization of intangible
asset
$14K
(-86.00%↓ Y/Y)
Buy us a coffee
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)